A drug approved in November as the first new treatment for advanced ovarian cancer in over seven years has now been shown to extend patients’ lives, its developer, Immunogen, said Wednesday.
Immunogen released data from a trial comparing the new drug, Elahere, to traditional chemotherapy in 453 ovarian cancer patients who had already progressed on at least one other therapy and had a particular protein marker on their tumor. Patients who received Elahere lived a median of 16.46 months, compared to 12.75 months for patients on chemotherapy.
Immunogen Chief Medical Officer Anna Berkenblit said in a statement that these data make Elahere the first drug to show a survival benefit in patients who progress after platinum chemotherapy.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
